LISTED medicinal cannabis provider Medlab has received confirmation from the Queensland and ACT health departments that the company's current Licence to Sell or Supply Schedule 8 or Schedule 9 Drugs allows Medlab to sell its NanaBis product in the respective territories.
Medlab ceo Sean Hall said the addition of the new jurisdictions means Medlab is now permitted to sell the cannabis-based NanaBis in its primary core territories, with only Tas and NT currently excluded.
"With these new territories and the logistics program for distribution of the NanaBis progressing as planned, Medlab is well positioned to have NanaBis ready for commercialisation under the Government's Special Access Scheme at the end of February 2018," Hall said.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 Feb 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Feb 18
